Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Effectiveness of Egg-derived Polyclonal Antibodies (IM-01) for the Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

NCT04121169 is registered in ClinicalTrials.gov with ImmuniMed Inc. as lead sponsor.

NCT NCT04121169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Effectiveness of Egg-derived Polyclonal Antibodies (IM-01) for the Treatment of Mild-moderate Clostridium Difficile Infection (CDI)
Lead sponsor
ImmuniMed Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 4, 2019
Completion date
March 30, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection (cdi)